Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations

Nature Communications

Volumn 5, Issue , 2014, Pages

  Nikolaev, Sergey I ^a   Garieri, Marco ^a   Santoni, Federico ^a,b   Falconnet, Emilie ^a   Ribaux, Pascale ^a   Guipponi, Michel ^b   Murray, Aoife ^c,d   Groet, Jürgen ^c,d   Giarin, Emanuela ^e   Basso, Giuseppe ^e   Nizetic, Dean ^c,d,f   Antonarakis, Stylianos E ^a,g  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e UNIVERSITY OF PADOVA   (Italy)

^f LEE KONG CHIAN SCHOOL OF MEDICINE   (Singapore)

^g Institute of Genetics and Genomics of Geneva   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE DIFFERENTIATION FACTOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; JANUS KINASE 2; PROTEIN TYROSINE PHOSPHATASE SHP 2; CHROMATIN; CRLF2 PROTEIN, HUMAN; CYTOKINE RECEPTOR; JAK2 PROTEIN, HUMAN; RAS PROTEIN;

BLOOD; BLOOD SYSTEM DISORDER; CANCER; CHILD HEALTH; CHROMOSOME; DISEASE TREATMENT; GENE EXPRESSION; MUTATION;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE DIFFERENTIATION FACTOR GENE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE INHIBITOR 2A GENE; CYTOKINE RECEPTOR LIKE FACTOR 2 GENE; DOWN SYNDROME; EXOME; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ANALYSIS; HISTONE DEACETYLASE 9 GENE; HUMAN; JANUS KINASE 2 GENE; LYMPHOCYTE DIFFERENTIATION; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NCOR1 GENE; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; P2RY8 GENE; PRIMARY TUMOR; PROTEIN TYROSINE PHOSPHATASE SHP 2 GENE; SOMATIC MUTATION; TUMOR GENE; TUMOR SUPPRESSOR GENE; CHEMISTRY; CHILD; CHROMATIN; CYTOLOGY; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTE; MALE; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE;

CHILD; CHROMATIN; DNA MUTATIONAL ANALYSIS; DOWN SYNDROME; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; JANUS KINASE 2; LYMPHOCYTES; MALE; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RAS PROTEINS; RECEPTORS, CYTOKINE;

EID: 84907341405     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5654     Document Type: Article

References (32)

1. Inaba, H., Greaves, M. & Mullighan, C. G. Acute lymphoblastic leukaemia. Lancet 381, 1943-1955 (2013).
2. Pui, C. H., Robison, L. L. & Look, A. T. Acute lymphoblastic leukaemia. Lancet 371, 1030-1043 (2008). (Pubitemid 351389536)
3. Hasle, H., Clemmensen, I. H. & Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355, 165-169 (2000). (Pubitemid 30068214)
4. Krivit, W. & Good, R. A. Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. AMA J. Dis. Child. 94, 289-293 (1957).
5. Zipursky, A., Poon, A. & Doyle, J. Leukemia in Down syndrome: a review. Pediatr. Hematol. Oncol. 9, 139-149 (1992).
6. Hasle, H. et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 17, 277-282 (2003). (Pubitemid 36266902)
7. Groet, J. et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 361, 1617-1620 (2003). (Pubitemid 36579001)
8. Malinge, S., Izraeli, S. & Crispino, J. D. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 113, 2619-2628 (2009).
9. Wechsler, J. et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat. Genet. 32, 148-152 (2002). (Pubitemid 34977210)
10. Bercovich, D. et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372, 1484-1492 (2008).
11. Hertzberg, L. et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115, 1006-1017 (2010).
12. Kearney, L. et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 113, 646-648 (2009).
13. Mullighan, C. G. et al. Rearrangement of CRLF2 in B-progenitor-and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 41, 1243-1246 (2009).
14. Buitenkamp, T. D. et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 123, 70-77 (2014).
15. Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242-252 (2013).
16. Nikolaev, S. I. et al. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood 122, 554-561 (2013).
17. Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012).
18. Yoshida, K. et al. The landscape of somatic mutations in Down syndromerelated myeloid disorders. Nat. Genet. 45, 1293-1299 (2013).
19. Grossmann, V. et al. High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia. Leukemia 27, 1933-1936 (2013).
20. Case, M. et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer. Res. 68, 6803-6809 (2008).
21. Papaemmanuil, E. et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat. Genet. 46, 116-125 (2014).
22. Zwaan, C. M. et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 99, 245-251 (2002).
23. Maloney, K. W. et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 116, 1045-1050 (2010).
24. Nizetic, D. & Groet, J. Tumorigenesis in Down's syndrome: big lessons from a small chromosome. Nat. Rev. Cancer 12, 721-732 (2012).
25. Buitenkamp, T. D. et al. BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia. Leukemia 27, 251-252 (2013).
26. Morak, M. et al. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. Blood 120, 5134-5142 (2012).
27. Zhang, J. et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 118, 3080-3087 (2011).
28. Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7, 295-308 (2007). (Pubitemid 46480970)
29. Baker, N. M. & Der, C. J. Cancer: Drug for an 'undruggable' protein. Nature 497, 577-578 (2013).
30. Nikolaev, S. I. et al. A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer Res. 72, 6279-6289 (2012).
31. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
32. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).